leon-nanodrugs, Bionpharma to Jointly Develop MJR Based Dermatological Product

leon-nanodrugs GmbH, a nanotechnology-based drug development company and Bionpharma Inc., a New Jersey-based integrated pharmaceutical company, announced the global cooperation for the development of a dermatological product using leon-nanodrugs' proprietary nanotechnology platform - MicroJet Reactor (MJR).

leon and Bionpharma will co-share the development of this important product. Development will be done at leon's US-based formulation partner CoreRx from Clearwater, Florida, a comprehensive contract development and manufacturing organization. CoreRx's facility houses leon-nanodrugs’ proprietary nanotechnology platform – MicroJet Reactor (MJR), thereby enabling leon to gain fast access to the key US market. Marketing and distribution of the product will be through Bionpharma in the US and other markets.

It is estimated that over 60% of pharmaceutical API's are poorly soluble in water. leon's MJR technology offers reformulation options that not only address this issue, but can also lead to a superior profile for the API by increasing bioavailability, reducing inter patient variability, improving onset of action, etc. The one-step, bottom up, continuous precipitation process approach of the MJR technology is highly cost effective and easily scalable.